We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead
Read MoreHide Full Article
Key Takeaways
Tempus AI's xT approval clears a path to unified ADLT pricing for its solid-tumor DNA portfolio.
Tempus expects xT pricing changes to add about $85 million in annual revenue starting in 2027.
xF could add further upside, with Tempus targeting roughly $400 million of combined uplift in 2028.
Tempus AI, Inc. (TEM - Free Report) has moved an important reimbursement catalyst closer to realization after receiving FDA approval for its tumor-only xT companion diagnostic. The approval gives the company a clearer route to higher pricing across its solid-tumor DNA portfolio.
The opportunity is meaningful, but much of the benefit is still ahead. Tempus must complete pricing transitions, secure additional regulatory approvals and broaden payer coverage before the full economics are reflected in results.
Year to date, Tempus AI shares have declined 7.8%, underperformed its industry.
Image Source: Zacks Investment Research
Tempus AI's FDA Approval Changes the Pricing Path
The xT approval enables Tempus to migrate its entire solid-tumor DNA portfolio to unified Advanced Diagnostic Laboratory Test, or ADLT, pricing. That materially improves visibility into a reimbursement thesis that previously depended on several separate steps.
Management expects the transition to lift average selling price by about $200 per test beginning in 2027. The approval therefore shifts part of the opportunity from regulatory possibility toward pricing execution.
TEM Could Gain $85 Million in Annual Revenue
Tempus estimates the xT pricing transition could add roughly $85 million in annual revenues beginning in 2027. That potential uplift is meaningful relative to a diagnostics business that generated $289.3 million of revenues in the second quarter of 2026.
The size of the opportunity raises the importance of implementation timing. Tempus still needs the ADLT migration to translate into realized reimbursement across its testing mix.
Tempus AI's xF Opportunity Adds Longer-Term Upside
The larger pricing opportunity may come from xF, Tempus' liquid biopsy assay now before the FDA. Management anticipates approval in the latter half of 2027 and assumes a $7,500 ADLT price, with roughly $550 of incremental average selling price uplift after approval and commercialization.
Guardant Health, Inc. (GH - Free Report) provides relevant industry context. In May 2026, Guardant received FDA approval for its expanded Guardant360 Liquid CDx, reinforcing the regulatory momentum around blood-based comprehensive genomic profiling.
TEM's Reimbursement Timeline Still Carries Risk
Most of the expected economics remain future-dated. Delays in xF approval, ADLT implementation or broader payer coverage could push revenue and margin benefits into later periods.
Reimbursement execution also matters in molecular residual disease testing. Natera, Inc. (NTRA - Free Report) , another oncology diagnostics company, reported continued growth in clinical MRD testing in the second quarter of 2026, underscoring both the demand opportunity and the competitive pace in this market.
Tempus AI's 2028 Upside Depends on Execution
Management anticipates approximately $400 million of combined revenue uplift from xT CDx and xF in 2028. Reaching that level requires Tempus to complete pricing transitions while commercializing xF and continuing to scale oncology, MRD and other growth initiatives.
The company is already balancing several priorities. Oncology volumes increased 31% year over year in the second quarter, while Data and Applications revenues rose 28%, so reimbursement gains would need to arrive without disrupting broader execution.
TEM's Hold Signal Keeps the FDA Upside in Context
The FDA approval improves Tempus' reimbursement visibility, but it does not remove timing, valuation or execution risk. The central question is whether the company can convert regulatory progress into durable pricing gains over the next two years.
Image Source: Zacks Investment Research
TEM currently carries a Zacks Rank #3 (Hold). It also has a VGM Score of F, Value Score of F, Growth Score of F and Momentum Score of D. A Zacks Rank #3 can support maintaining an existing position, while the weak Style Scores indicate less favorable value, growth and momentum characteristics than stocks with higher grades. Together, those signals keep the reimbursement upside in perspective rather than turning the FDA catalyst into a stand-alone investment case.
View the Zacks #1 Rank List
Image: Bigstock
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead
Key Takeaways
Tempus AI, Inc. (TEM - Free Report) has moved an important reimbursement catalyst closer to realization after receiving FDA approval for its tumor-only xT companion diagnostic. The approval gives the company a clearer route to higher pricing across its solid-tumor DNA portfolio.
The opportunity is meaningful, but much of the benefit is still ahead. Tempus must complete pricing transitions, secure additional regulatory approvals and broaden payer coverage before the full economics are reflected in results.
Year to date, Tempus AI shares have declined 7.8%, underperformed its industry.
Image Source: Zacks Investment Research
Tempus AI's FDA Approval Changes the Pricing Path
The xT approval enables Tempus to migrate its entire solid-tumor DNA portfolio to unified Advanced Diagnostic Laboratory Test, or ADLT, pricing. That materially improves visibility into a reimbursement thesis that previously depended on several separate steps.
Management expects the transition to lift average selling price by about $200 per test beginning in 2027. The approval therefore shifts part of the opportunity from regulatory possibility toward pricing execution.
TEM Could Gain $85 Million in Annual Revenue
Tempus estimates the xT pricing transition could add roughly $85 million in annual revenues beginning in 2027. That potential uplift is meaningful relative to a diagnostics business that generated $289.3 million of revenues in the second quarter of 2026.
The size of the opportunity raises the importance of implementation timing. Tempus still needs the ADLT migration to translate into realized reimbursement across its testing mix.
Tempus AI's xF Opportunity Adds Longer-Term Upside
The larger pricing opportunity may come from xF, Tempus' liquid biopsy assay now before the FDA. Management anticipates approval in the latter half of 2027 and assumes a $7,500 ADLT price, with roughly $550 of incremental average selling price uplift after approval and commercialization.
Guardant Health, Inc. (GH - Free Report) provides relevant industry context. In May 2026, Guardant received FDA approval for its expanded Guardant360 Liquid CDx, reinforcing the regulatory momentum around blood-based comprehensive genomic profiling.
TEM's Reimbursement Timeline Still Carries Risk
Most of the expected economics remain future-dated. Delays in xF approval, ADLT implementation or broader payer coverage could push revenue and margin benefits into later periods.
Reimbursement execution also matters in molecular residual disease testing. Natera, Inc. (NTRA - Free Report) , another oncology diagnostics company, reported continued growth in clinical MRD testing in the second quarter of 2026, underscoring both the demand opportunity and the competitive pace in this market.
Tempus AI's 2028 Upside Depends on Execution
Management anticipates approximately $400 million of combined revenue uplift from xT CDx and xF in 2028. Reaching that level requires Tempus to complete pricing transitions while commercializing xF and continuing to scale oncology, MRD and other growth initiatives.
The company is already balancing several priorities. Oncology volumes increased 31% year over year in the second quarter, while Data and Applications revenues rose 28%, so reimbursement gains would need to arrive without disrupting broader execution.
TEM's Hold Signal Keeps the FDA Upside in Context
The FDA approval improves Tempus' reimbursement visibility, but it does not remove timing, valuation or execution risk. The central question is whether the company can convert regulatory progress into durable pricing gains over the next two years.
Image Source: Zacks Investment Research
TEM currently carries a Zacks Rank #3 (Hold). It also has a VGM Score of F, Value Score of F, Growth Score of F and Momentum Score of D. A Zacks Rank #3 can support maintaining an existing position, while the weak Style Scores indicate less favorable value, growth and momentum characteristics than stocks with higher grades. Together, those signals keep the reimbursement upside in perspective rather than turning the FDA catalyst into a stand-alone investment case.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.